These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 29584848)

  • 41. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
    Jotwani V; Scherzer R; Glidden DV; Mehrotra M; Defechereux P; Liu A; Gandhi M; Bennett M; Coca SG; Parikh CR; Grant RM; Shlipak MG
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):169-174. PubMed ID: 29767638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
    Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM
    Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
    Pornpaisalsakul K; Songtaweesin WN; Tepmongkol S; Wongharn P; Kawichai S; Suponsilchai V; Anugulruengkitt S; Puthanakit T;
    J Int AIDS Soc; 2020 Oct; 23(10):e25624. PubMed ID: 33040465
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.
    Tanner MR; Miele P; Carter W; Valentine SS; Dunville R; Kapogiannis BG; Smith DK
    MMWR Recomm Rep; 2020 Apr; 69(3):1-12. PubMed ID: 32324724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
    Donnell D; Baeten JM; Bumpus NN; Brantley J; Bangsberg DR; Haberer JE; Mujugira A; Mugo N; Ndase P; Hendrix C; Celum C
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):340-8. PubMed ID: 24784763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
    Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
    Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention.
    Mayer KH; Allan-Blitz LT
    J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 2(2):S113-S117. PubMed ID: 31658197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA
    Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
    O Murchu E; Marshall L; Teljeur C; Harrington P; Hayes C; Moran P; Ryan M
    BMJ Open; 2022 May; 12(5):e048478. PubMed ID: 35545381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
    Mofenson LM; Baggaley RC; Mameletzis I
    AIDS; 2017 Jan; 31(2):213-232. PubMed ID: 27831952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men.
    McManus H; Grulich AE; Amin J; Selvey C; Vickers T; Bavinton B; Zablotska I; Vaccher S; Jin F; Holden J; Price K; Yeung B; Cabrera Quichua G; Ogilvie E; McNulty A; Smith D; Guy R
    JAMA Netw Open; 2020 Dec; 3(12):e2030806. PubMed ID: 33355675
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.